- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma | NEJM nejm.org
- Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study The Lancet
- Neoadjuvant Pembrolizumab for Advanced Melanoma | NEJM nejm.org
- View Full Coverage on Google News